Please assess the completion status of the following clinical trial:

Trial Title: Versartis Long-Term Safety Study of Somavaratan

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Subjects Completing a Previous Somavaratan Study:~1. Completion of a somavaratan clinical study.~2. Willing and able to comply with all study procedures.~Exclusion Criteria for Subjects Completing a Previous somavaratan Study:~1. Withdrawal from a somavaratan clinical study.~2. Use of certain medications with potential to alter responses to the test product.~3. Presence of a significant medical condition.~Inclusion Criteria for New Treatment Naïve Subjects:~1. Chronological Age ≥ 3.0 years.~2. Pre-pubertal status.~3. Diagnosis of GHD as documented by two or more GH stimulation test results ≤ 10.0 ng/mL.~4. Normal thyroid function at Screening Visit in subjects not being treated for hypothyroidism.~5. Normal adrenal function at Screening Visit or within 6 months of the Screening Visit, in subjects not being treated for adrenal insufficiency. Subjects with adrenal insufficiency must receive glucocorticoid treatment for a minimum of 4 weeks before study drug administration.~6. Pathology relating to cause of GHD must be stable for at least 6 months prior to screening.~7. Legally authorized representatives must be willing and able to give informed consent.~Exclusion Criteria for New Treatment Naïve Subjects:~1. Prior/concomitant treatment with any growth promoting agent.~2. Current, significant disease.~3. Chromosomal aneuploidy, significant gene mutations or confirmed diagnosis of a named syndrome.~4. Birth weight and/or birth length less than 5th percentile for gestational age.~5. Prolonged daily use of anti-inflammatory doses of oral glucocorticoids.~6. Prior history of malignancy.~7. Treatment with an investigational drug in the 30 days prior to screening.~8. Known allergy to constituents of the study drug formulation.~9. Ocular findings suggestive of increased intracranial pressure and/or retinopathy at screening.~10. Significant spinal abnormalities including scoliosis, kyphosis, Chiari malformation, and spina bifida variants.~11. Significant abnormality in screening studies.~12. History of pancreatitis or undiagnosed chronic abdominal pain.~13. History of spinal or total body irradiation.~14. Other pituitary hormone deficiencies that are not properly treated.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment naive subjects with GHD (Type: EXPERIMENTAL): Up to 100 new treatment naïve subjects with GHD will receive somavaratan 3.5mg/kg twice monthly.
- Subjects who have completed a somavaratan study (Type: EXPERIMENTAL): All subjects after participation in (12VR2) or participation in the 14VR4 protocols have the option to receive somavaratan 3.5mg/kg twice monthly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy